+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Eczema Therapeutics Market by Indication and Geography - Forecast and Analysis 2020-2024 - Product Image

Eczema Therapeutics Market by Indication and Geography - Forecast and Analysis 2020-2024

  • ID: 4895830
  • Report
  • December 2019
  • Region: Global
  • 152 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie Inc.
  • Alliance Pharma Plc
  • Bayer AG
  • Eli Lilly Co.
  • Encore Dermatology Inc.
  • LEO Pharma AS
  • MORE
Global Eczema Therapeutics Market: About this market
The eczema therapeutics market analysis considers sales from atopic dermatitis, contact dermatitis, and other indication. Our study also finds the sales of eczema therapeutics in Asia, Europe, North America, and ROW. In 2019, the atopic dermatitis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of chronic, highly pruritic inflammatory skin disorders will play a significant role in the atopic dermatitis segment to maintain its market position. Also, our global eczema therapeutics market report looks at factors such as the high prevalence of atopic dermatitis, strong pipeline landscapes, and major product launches. However, side effects associated with corticosteroids, intense competition among vendors, and stringent regulatory guidelines may hamper the growth of the eczema therapeutics industry over the forecast period.

Global Eczema Therapeutics Market: Overview

High prevalence of atopic dermatitis
Exposure to skin irritants including soaps or cleaners and allergens such as pet dander, pollen, or peanuts can lead to eczema. It is also caused by infections, dry skin, and stress. Atopic dermatitis is one of the most prevalent forms of eczema which requires multiple visits to dermatologists and numerous medications for treatment. China, India, and Japan are the three major revenue contributors to the market as these regions of Asia constitute a huge patient pool and consequently exhibit a high demand for eczema therapeutics. Thus, the high prevalence of atopic dermatitis will lead to the expansion of the global eczema therapeutics market at a CAGR of over 9% during the forecast period.

Increasing healthcare expenditure
Healthcare expenditure is increasing owing to the growing prevalence of allergic and inflammatory skin diseases in people globally. For the treatment of highly prevalent diseases such as atopic dermatitis, dermatologists are prescribing many OTC drugs and generic medications such as corticosteroids, antihistamines, and topical antiseptics due to the high number of clinical visits. The market is also witnessing an increased adoption of expensive, novel, and branded drugs for a more effective treatment. Moreover, the growing awareness of the need for early diagnosis of skin diseases, as well as the risks of negligence in seeking timely medical help, is making people increasingly health-conscious, which, in turn, is organically increasing the healthcare expenditure.

Competitive Landscape
With the presence of several major players, the global eczema therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading eczema therapeutics manufacturers, that include AbbVie Inc., Alliance Pharma Plc, Bausch Health Companies Inc., Bayer AG, Eli Lilly and Co., Encore Dermatology Inc., LEO Pharma AS, Mylan NV, Pfizer Inc., and Sanofi.

Also, the eczema therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Alliance Pharma Plc
  • Bayer AG
  • Eli Lilly Co.
  • Encore Dermatology Inc.
  • LEO Pharma AS
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value chain analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: CUSTOMER LANDSCAPE

PART 07: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity
PART 08: MARKET SEGMENTATION BY INDICATION
  • Market segmentation by indication
  • Comparison by indication
  • Atopic dermatitis - Market size and forecast 2019-2024
  • Contact dermatitis - Market size and forecast 2019-2024
  • Other indication - Market size and forecast 2019-2024
  • Market opportunity by indication
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Business strategies
  • Geopolitical uncertainties
  • Increasing healthcare expenditure
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Alliance Pharma Plc
  • Bausch Health Companies Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • Encore Dermatology Inc.
  • LEO Pharma AS
  • Mylan NV
  • Pfizer Inc.
  • Sanofi
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Vendors: Key Offerings
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2019
Exhibit 18: Customer landscape
Exhibit 19: Market share by geography 2019-2024 (%)
Exhibit 20: Geographic comparison
Exhibit 21: North America - Market size and forecast 2019-2024 ($ millions)
Exhibit 22: North America - Year-over-year growth 2020-2024 (%)
Exhibit 23: Top 3 countries in North America
Exhibit 24: Europe - Market size and forecast 2019-2024 ($ millions)
Exhibit 25: Europe - Year-over-year growth 2020-2024 (%)
Exhibit 26: Top 3 countries in Europe
Exhibit 27: Asia - Market size and forecast 2019-2024 ($ millions)
Exhibit 28: Asia - Year-over-year growth 2020-2024 (%)
Exhibit 29: Top 3 countries in Asia
Exhibit 30: ROW - Market size and forecast 2019-2024 ($ millions)
Exhibit 31: ROW - Year-over-year growth 2020-2024 (%)
Exhibit 32: Top 3 countries in ROW
Exhibit 33: Key leading countries
Exhibit 34: Market opportunity
Exhibit 35: Indication - Market share 2019-2024 (%)
Exhibit 36: Comparison by indication
Exhibit 37: Atopic dermatitis - Market size and forecast 2019-2024 ($ millions)
Exhibit 38: Atopic dermatitis - Year-over-year growth 2020-2024 (%)
Exhibit 39: Contact dermatitis - Market size and forecast 2019-2024 ($ millions)
Exhibit 40: Contact dermatitis - Year-over-year growth 2020-2024 (%)
Exhibit 41: Other indication - Market size and forecast 2019-2024 ($ millions)
Exhibit 42: Other indication - Year-over-year growth 2020-2024 (%)
Exhibit 43: Market opportunity by indication
Exhibit 44: Product launch details
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Business strategies
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: AbbVie Inc. - Vendor overview
Exhibit 53: AbbVie Inc. - Business segments
Exhibit 54: AbbVie Inc. - Organizational developments
Exhibit 55: AbbVie Inc. - Geographic focus
Exhibit 56: AbbVie Inc. - Key offerings
Exhibit 57: AbbVie Inc. - Key customers
Exhibit 58: Alliance Pharma Plc - Vendor overview
Exhibit 59: Alliance Pharma Plc - Business segments
Exhibit 60: Alliance Pharma Plc - Organizational developments
Exhibit 61: Alliance Pharma Plc - Geographic focus
Exhibit 62: Alliance Pharma Plc - Segment focus
Exhibit 63: Alliance Pharma Plc - Key offerings
Exhibit 64: Alliance Pharma Plc - Key customers
Exhibit 65: Bausch Health Companies Inc. - Vendor overview
Exhibit 66: Bausch Health Companies Inc. - Business segments
Exhibit 67: Bausch Health Companies Inc. - Organizational developments
Exhibit 68: Bausch Health Companies Inc. - Geographic focus
Exhibit 69: Bausch Health Companies Inc. - Segment focus
Exhibit 70: Bausch Health Companies Inc. - Key offerings
Exhibit 71: Bausch Health Companies Inc. - Key customers
Exhibit 72: Bayer AG - Vendor overview
Exhibit 73: Bayer AG - Business segments
Exhibit 74: Bayer AG - Organizational developments
Exhibit 75: Bayer AG - Geographic focus
Exhibit 76: Bayer AG - Segment focus
Exhibit 77: Bayer AG - Key offerings
Exhibit 78: Bayer AG - Key customers
Exhibit 79: Eli Lilly and Co. - Vendor overview
Exhibit 80: Eli Lilly and Co. - Business segments
Exhibit 81: Eli Lilly and Co. - Organizational developments
Exhibit 82: Eli Lilly and Co. - Geographic focus
Exhibit 83: Eli Lilly and Co. - Segment focus
Exhibit 84: Eli Lilly and Co. - Key offerings
Exhibit 85: Eli Lilly and Co. - Key customers
Exhibit 86: Encore Dermatology Inc. - Vendor overview
Exhibit 87: Encore Dermatology Inc. - Product segments
Exhibit 88: Encore Dermatology Inc. - Organizational developments
Exhibit 89: Encore Dermatology Inc. - Key offerings
Exhibit 90: Encore Dermatology Inc. - Key customers
Exhibit 91: LEO Pharma AS - Vendor overview
Exhibit 92: LEO Pharma AS - Product segments
Exhibit 93: LEO Pharma AS - Organizational developments
Exhibit 94: LEO Pharma AS - Key offerings
Exhibit 95: LEO Pharma AS - Key customers
Exhibit 96: Mylan NV - Vendor overview
Exhibit 97: Mylan NV - Product segments
Exhibit 98: Mylan NV - Organizational developments
Exhibit 99: Mylan NV - Geographic focus
Exhibit 100: Mylan NV - Segment focus
Exhibit 101: Mylan NV - Key offerings
Exhibit 102: Mylan NV - Key customers
Exhibit 103: Pfizer Inc. - Vendor overview
Exhibit 104: Pfizer Inc. - Business segments
Exhibit 105: Pfizer Inc. - Organizational developments
Exhibit 106: Pfizer Inc. - Geographic focus
Exhibit 107: Pfizer Inc. - Segment focus
Exhibit 108: Pfizer Inc. - Key offerings
Exhibit 109: Pfizer Inc. - Key customers
Exhibit 110: Sanofi - Vendor overview
Exhibit 111: Sanofi - Business segments
Exhibit 112: Sanofi - Organizational developments
Exhibit 113: Sanofi - Geographic focus
Exhibit 114: Sanofi - Segment focus
Exhibit 115: Sanofi - Key offerings
Exhibit 116: Sanofi - Key customers
Exhibit 117: Validation techniques employed for market sizing
Exhibit 118: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Alliance Pharma Plc
  • Bayer AG
  • Eli Lilly Co.
  • Encore Dermatology Inc.
  • LEO Pharma AS
  • MORE
The following companies as the key players in the global eczema therapeutics market: AbbVie Inc., Alliance Pharma Plc, Bausch Health Companies Inc., Bayer AG, Eli Lilly and Co., Encore Dermatology Inc., LEO Pharma AS, Mylan NV, Pfizer Inc., and Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing healthcare expenditure.”

According to the report, one of the major drivers for this market is the high prevalence of atopic dermatitis.

Further, the report states that one of the major factors hindering the growth of this market is the intense competition among vendors.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AbbVie Inc.
  • Alliance Pharma Plc
  • Bausch Health Companies Inc.
  • Bayer AG
  • Eli Lilly Co.
  • Encore Dermatology Inc.
  • LEO Pharma AS
  • Mylan NV
  • Pfizer Inc.
  • Sanofi.
Note: Product cover images may vary from those shown
Adroll
adroll